Project Grant R44CA192875

This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...

This $550,296 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to develop a multimodal imaging diagnostic platform to improve risk assessment of precancerous oral lesions. The key products and services to be delivered under this grant include: Development of machine learning and deep learning models using Fourier transform infrared (FTIR) imaging techniques for risk...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $294,505 to support the development and commercialization of a targeted fluorescence dye for intraoperative imaging and precision surgical treatment of head and neck cancer (HNC). The goal is to create a small peptide-based fluorescent probe that can specifically stain HNC tumors to assist surgeons in identifying tumors...

The National Cancer Institute awarded a $957,152 Cooperative Agreement under the Cancer Detection and Diagnosis Research (CFDA 93.394) program to GE Medical Systems Information Technologies, Inc. to develop and deploy an affordable automated point-of-care telecytology platform for oral cancer screening in India. The project aims to reliably establish a diagnosis of oral cancer in the community setting and create an immediate referral care pathway. Key components include a portable system for...

The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,564,226 Project Grant (CFDA 93.121 - Oral Diseases and Disorders Research) to Virginia Commonwealth University (VCU) to investigate the role of FOSL1 super-enhancers in cisplatin-enriched cancer stem cells (CSCs) in head and neck squamous cell carcinoma (HNSCC). The key objectives are to: 1) examine the mechanism by which FOSL1 super-enhancers determine the functional properties of cisplatin-enriched CSCs, and...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $204,688 to The Johns Hopkins University to develop a novel immunotherapy approach for treating HPV-associated head and neck cancers. The key products and services to be delivered under this award include: 1) Evaluating the ability of Salmonella-derived nanoparticles coated with the HPV E7 antigen (SOMV-9RE7) to induce...

This $598,332 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, will support research to investigate the role of the truncated TrkB isoform (TrkBT1) in oral cancer pain. The primary awardee, the University of Texas Health Science Center at San Antonio (UTHSCSA), will conduct studies to examine how TrkBT1 expressed in trigeminal sensory neurons and oral squamous cell carcinoma (OSCC)...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports a Phase I clinical trial to evaluate the safety and efficacy of CSPG4-targeted CAR-T cell therapy in adult patients with head and neck squamous cell carcinoma (HNSCC) that is refractory to platinum and PD-1 inhibitor treatment. The award of $627,456 will fund the single-center, open-label clinical trial over a 5-year period from December 2024 to November 2029....

The National Institute of Dental and Craniofacial Research (NIDCR) awarded Keraceuticals, Inc. a $799,270 Project Grant (CFDA 93.121 - Oral Diseases and Disorders Research) to develop a novel class of anticancer drugs called 1,3-thioureas for the treatment of oral squamous cell carcinoma (OSCC). The funding will support formulating the lead compound CIDD99 for oral and/or intravenous administration, confirming its efficacy in mouse OSCC models, and evaluating its combination with...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $234,750 to Emory University to study the ability of the IAP antagonist tolinapant to enhance radiation therapy-stimulated abscopal anti-tumor immune responses in head and neck cancer models. The research aims to determine if tolinapant can increase stem-like CD8+ T cells in tumor-draining lymph nodes, leading to systemic...